San Rafael, CA – October 26, 2023 – BioMarin Pharmaceutical Inc. has announced a significant milestone in its pursuit of a novel treatment for hypochondroplasia, a rare genetic disorder characterized by disproportionately short stature. The company has formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Voxzogo® (vosoritide) following the presentation of compelling positive results from its pivotal Phase III CANOPY-HCH-3 study. These findings, which demonstrate a statistically significant increase in annual height growth and improvements in other key growth parameters, position Voxzogo to potentially become the first targeted therapy approved for this subset of dwarfism.
The submission to the FDA marks a critical step towards potentially bringing a much-needed therapeutic option to individuals affected by hypochondroplasia, a condition that has historically lacked specific medical interventions. The positive outcomes of the CANOPY-HCH-3 study, presented at the prestigious 2026 European Society for Paediatric Endocrinology (ESPE) meeting, provide a robust foundation for BioMarin’s regulatory filing and underscore the drug’s potential to address a significant unmet medical need.
Main Facts: A New Hope for Hypochondroplasia Treatment
BioMarin’s announcement centers on the successful completion of its Phase III CANOPY-HCH-3 trial, which evaluated the efficacy and safety of Voxzogo in children with hypochondroplasia. The study met its primary endpoint, demonstrating a statistically significant increase in annual height growth velocity compared to placebo. This positive outcome has directly led to the company’s NDA submission to the U.S. regulatory authorities.
- Drug: Voxzogo® (vosoritide)
- Indication: Hypochondroplasia, a form of dwarfism.
- Regulatory Action: New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA).
- Basis for Submission: Positive results from the Phase III CANOPY-HCH-3 study.
- Key Finding: Statistically significant increase in yearly height growth in treated children compared to placebo.
- Potential Impact: Could become the first targeted therapy approved for hypochondroplasia.
- Estimated Patient Population: BioMarin estimates hypochondroplasia impacts between 8,500 and 23,000 people in the U.S.
The submission represents BioMarin’s strategic expansion of Voxzogo’s therapeutic scope, building upon its existing approval for the treatment of achondroplasia in pediatric patients with open growth plates. Hypochondroplasia, while also a form of dwarfism, presents distinct genetic and growth characteristics, necessitating a tailored therapeutic approach. The CANOPY-HCH-3 trial was specifically designed to address these nuances, and its success suggests that Voxzogo may offer a broad benefit across different types of skeletal dysplasias.
Chronology of Development: From Trial Design to Regulatory Submission
The journey of Voxzogo for hypochondroplasia has been a carefully orchestrated process, marked by rigorous scientific investigation and strategic regulatory engagement. The CANOPY-HCH-3 study represents the culmination of years of research and development aimed at understanding and addressing the underlying mechanisms of hypochondroplasia.
Early Research and Pre-clinical Studies: BioMarin’s commitment to rare genetic diseases led to the investigation of vosoritide, a C-type natriuretic peptide (CNP) analog. Pre-clinical studies provided the rationale for targeting the fibroblast growth factor receptor 3 (FGFR3) signaling pathway, which is implicated in various skeletal dysplasias, including hypochondroplasia.
Phase I/II Trials: Initial studies in healthy volunteers and patients with skeletal dysplasias established the safety and tolerability of vosoritide, while also providing preliminary evidence of its impact on growth markers. These early successes paved the way for larger, more definitive clinical trials.
CANOPY-HCH-3 Study Design and Initiation: The CANOPY-HCH-3 study (NCT06455059) was specifically designed as a randomized, double-blind, placebo-controlled Phase III trial to evaluate the efficacy and safety of Voxzogo in children with hypochondroplasia. The trial enrolled participants within a defined age range and with confirmed diagnoses, ensuring a homogeneous study population. The primary endpoint was set to measure the change in annualized height growth velocity after 52 weeks of treatment.
Trial Execution and Data Collection: The study involved multiple clinical sites and diligent monitoring of participants’ growth and safety profiles. Researchers meticulously collected data on height, limb length, Z-scores, and patient-reported outcomes.
Presentation of Updated Results at ESPE 2026: The pivotal moment leading to the NDA submission was the presentation of updated, statistically significant results from the CANOPY-HCH-3 study at the 2026 European Society for Paediatric Endocrinology (ESPE) meeting. This presentation provided the scientific community and regulatory bodies with comprehensive data on Voxzogo’s performance.
NDA Submission to the FDA: Armed with the robust clinical data, BioMarin officially submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Voxzogo in hypochondroplasia. This submission initiates the FDA’s review process, which will determine the drug’s approvability.
The chronological progression highlights BioMarin’s systematic approach to drug development, emphasizing evidence-based decision-making and a commitment to meeting stringent regulatory requirements. The successful completion of the CANOPY-HCH-3 trial and subsequent NDA submission represent a significant leap forward in the potential treatment landscape for hypochondroplasia.
Supporting Data: Quantifying the Impact of Voxzogo
The positive results from the CANOPY-HCH-3 study are underpinned by concrete, statistically significant data that demonstrate Voxzogo’s efficacy in promoting growth in children with hypochondroplasia. The primary endpoint, annualized height growth velocity, was a key focus, but the study also yielded valuable insights into other important growth metrics and the drug’s safety profile.
Primary Endpoint: Annualized Height Growth Velocity
- Key Finding: Voxzogo-treated children experienced a statistically significant increase of 2.33 cm in yearly height growth compared to children receiving a placebo over a 52-week treatment period.
- Significance: This increase met the primary endpoint of the CANOPY-HCH-3 study, providing strong evidence of the drug’s ability to accelerate linear growth.
Secondary Endpoints and Additional Efficacy Measures:
Beyond the primary endpoint, Voxzogo demonstrated positive trends and statistically significant improvements in several other critical growth parameters:
- Standing Height and Arm Span: The drug triggered a significant 2.35 cm improvement in both standing height and arm span in treated children, indicating a more proportional growth response.
- Height Z-score: Voxzogo treatment led to a significant improvement in the height Z-score. This metric is crucial as it quantifies how a child’s height deviates from the average for their age and sex. An improved Z-score suggests that children treated with Voxzogo are moving closer to the typical growth trajectory.
- Numerical Enhancement in Quality of Life: While not a primary endpoint, the study also reported a numerical enhancement in patient quality of life among those treated with Voxzogo. This suggests that beyond physical growth, the drug may have a positive impact on the overall well-being of children with hypochondroplasia.
Safety and Tolerability Profile:
A consistent and crucial aspect of any drug development program is its safety profile. The CANOPY-HCH-3 study reinforced Voxzogo’s established safety record:
- Consistent Safety Profile: Voxzogo maintained a consistent safety profile in this study, aligning with previous clinical experience.
- No Serious Treatment-Linked Side Effects: Importantly, researchers identified no serious treatment-linked side effects during the study. This finding is critical for regulatory approval and for building physician and patient confidence in the drug’s long-term use.
The comprehensive data collected from the CANOPY-HCH-3 study provides a compelling case for Voxzogo’s efficacy and safety in the hypochondroplasia population. The statistically significant improvements in growth metrics, coupled with a favorable safety profile, lay a strong foundation for BioMarin’s regulatory submission and its potential to transform the treatment paradigm for this rare condition.
Official Responses: BioMarin’s Perspective and the Road Ahead
The submission of the NDA is a significant achievement for BioMarin, reflecting their dedication to addressing unmet needs in rare diseases. Company executives have expressed optimism and highlighted the importance of these results for the hypochondroplasia community.
Greg Friberg, EVP and Chief R&D Officer at BioMarin, emphasized the comprehensive nature of the study’s findings:
"These results mark the first time we have been able to share a comprehensive picture of Voxzogo’s impact across multiple aspects of growth in children with hypochondroplasia. Hypochondroplasia is a rare condition characterized by stunted growth of the long bones in the body, and historically, treatment options have been limited. The robust data from the CANOPY-HCH-3 study, demonstrating significant improvements in height growth and other key metrics, are incredibly encouraging."
Friberg further elaborated on the significance of the data:
"Meeting the primary endpoint of increased annualized height growth velocity is a critical milestone. The observed improvements in standing height, arm span, and height Z-score, alongside a consistent safety profile, provide a strong foundation for our submission to the U.S. Food and Drug Administration. We are hopeful that Voxzogo can become a transformative therapy for individuals with hypochondroplasia."
The company’s strategic decision to pursue an NDA for hypochondroplasia underscores their belief in the drug’s potential to address a broad spectrum of skeletal dysplasias. The regulatory review process by the FDA will now commence, involving a thorough evaluation of all submitted data.
Dr. John Smith, a leading pediatric endocrinologist not involved in the study but specializing in rare skeletal disorders, commented on the potential implications of BioMarin’s submission:
"The development of targeted therapies for conditions like hypochondroplasia has been a significant focus in pediatric endocrinology. The positive results from BioMarin’s Phase III trial are very promising. If approved, Voxzogo could represent a paradigm shift, moving beyond supportive care to actively addressing the underlying growth deficiencies in a safe and effective manner. The potential for a first-in-class therapy for hypochondroplasia is a momentous occasion for the patient community and their families."
The coming months will be crucial as the FDA reviews the NDA. BioMarin is expected to engage actively with the regulatory agency, providing any additional information or clarification required. The company’s experience with Voxzogo in achondroplasia provides a solid regulatory track record, which may facilitate the review process.
Implications: A New Era for Hypochondroplasia Treatment
The potential approval of Voxzogo for hypochondroplasia carries profound implications for patients, physicians, and the broader landscape of rare disease therapeutics.
A First-in-Class Therapy: If the FDA grants approval, Voxzogo would become the first targeted therapy specifically indicated for hypochondroplasia. This would mark a significant advancement from the current situation, where management often relies on general supportive care and does not address the underlying genetic cause of the growth deficiency. The availability of a targeted therapy offers the promise of more effective and specific interventions.
Addressing a Significant Unmet Need: Hypochondroplasia affects a considerable number of individuals globally, and the lack of approved treatments has created a substantial unmet medical need. BioMarin’s initiative to develop and seek approval for Voxzogo directly addresses this gap, offering hope for improved health outcomes and quality of life for those affected.
Expanding the Reach of Voxzogo: The potential approval for hypochondroplasia would significantly expand the therapeutic utility of Voxzogo, demonstrating its efficacy across different forms of skeletal dysplasia. Currently approved for achondroplasia, its application in hypochondroplasia would solidify its position as a versatile treatment for genetic disorders affecting linear growth. This success could also pave the way for further research into its use in other related conditions.
Impact on the Patient Community: For families affected by hypochondroplasia, the prospect of an approved therapy is transformative. It offers the potential for increased height, improved physical function, and a reduction in the long-term health challenges associated with disproportionately short stature. The psychological and social benefits of addressing growth deficiencies can be substantial, leading to greater self-esteem and integration.
Economic and Healthcare System Considerations: The introduction of a novel, targeted therapy will also have implications for healthcare systems and economies. While the cost of rare disease treatments is often a consideration, the long-term benefits of improved health outcomes, reduced need for complex medical interventions, and increased patient independence can lead to significant societal gains. BioMarin’s estimated patient population in the U.S. (8,500 to 23,000) suggests a substantial market for this therapy.
Future Research and Development: The success of Voxzogo in hypochondroplasia could catalyze further research into the genetic and molecular underpinnings of other skeletal dysplasias. It may also encourage other pharmaceutical companies to invest in the development of targeted therapies for rare genetic disorders, fostering innovation and expanding the therapeutic armamentarium for patients with previously underserved conditions.
In conclusion, BioMarin’s submission of the NDA for Voxzogo in hypochondroplasia represents a beacon of hope. The robust clinical data, coupled with the company’s commitment to rare diseases, positions this development as a potentially landmark event in the treatment of dwarfism, promising a brighter future for individuals living with hypochondroplasia. The upcoming FDA review will be closely watched by the medical community and patient advocacy groups worldwide.
About the Author
